# Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects

> **NCT06198556** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HRS-1167 tablets; rifampicin

## Key facts

- **NCT ID:** NCT06198556
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-14
- **Primary completion:** 2024-02-05
- **Final completion:** 2024-02-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06198556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06198556, "Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06198556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*